← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors
deuruxolitinib
L04AF09
Forms & Strengths
- Oral tablets: 8 mg
- Oral tablets: 15 mg
Adult Dosing
- Severe alopecia areata: 8 mg orally twice daily
- Severe alopecia areata: Can increase to 12 mg orally twice daily if efficacy is inadequate after 24 weeks
- Maximum dose: 12 mg twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients below 18 years of age have not been established
Indications
- Treatment of severe alopecia areata in adult patients
Mechanism of Action
- Selective inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2)
- Disrupts cytokine signaling pathways involved in the autoimmune destruction of hair follicles
Contraindications
- Active serious infection, including tuberculosis
- Severe hepatic impairment
- Known hypersensitivity to deuruxolitinib or any of its excipients
- Pregnancy and lactation
Adverse Reactions
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Blood creatine phosphokinase (CPK) elevation
- Acne
- Urinary tract infection
- Increased risk of serious infections, malignancies, and thrombosis
Drug Interactions
- Strong CYP2C9 inhibitors may increase deuruxolitinib exposure
- Strong CYP2C9 inducers may decrease deuruxolitinib efficacy
- Avoid concurrent use with strong immunosuppressants (e.g., biologic DMARDs, cyclosporine) due to risk of additive immunosuppression
Curated Content: Needs Vetting Before Put to Clinical Use